Systemic adverse effects of topical ocular treatments

Presse Medicale

Volumn 34, Issue 8, 2005, Pages 589-595

  Labetoulle, Marc ^a   Frau, Éric ^a   Le Jeunne, Claire ^b  

^a BICÊTRE HOSPITAL   (France)

^b HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIBIOTIC AGENT; ANTIGLAUCOMA AGENT; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; CHLORAMPHENICOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; CYCLOPLEGIC AGENT; DEXAMETHASONE; EYE DROPS; EYE OINTMENT; MONOAMINE OXIDASE INHIBITOR; MUSCARINIC AGENT; MYDRIATIC AGENT; NEOMYCIN; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN UPTAKE INHIBITOR; PHYSOSTIGMINE; POLYMYXIN B; PROSTAGLANDIN DERIVATIVE; QUINOLONE DERIVATIVE; RIFAMPICIN; STEROID; TIMOLOL; TOPICAL ANTIINFECTIVE AGENT;

ABDOMINAL CRAMP; AIRWAY OBSTRUCTION; ALOPECIA; ANAPHYLAXIS; ANGINA PECTORIS; ANXIETY DISORDER; APNEA; ARTHROPATHY; ASTHMA; ATAXIA; BITTER TASTE; BRADYCARDIA; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; COMA; CONFUSION; CONVULSION; DEPRESSION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG OVERDOSE; DRUG PENETRATION; DRY NOSE; DRY SKIN; DYSARTHRIA; DYSLIPIDEMIA; DYSPNEA; FATIGUE; FEVER; FLUSHING; GASTROINTESTINAL SYMPTOM; GEL; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HEMATOLOGIC DISEASE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERADRENOCORTICISM; HYPERSALIVATION; HYPERTENSION; HYPERTHYROIDISM; HYPOGLYCEMIA; HYPOTENSION; HYPOTHERMIA; IATROGENIC DISEASE; IMPOTENCE; IRRITABILITY; LIBIDO DISORDER; LUNG INSUFFICIENCY; MIGRAINE; MYALGIA; MYASTHENIA GRAVIS; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PAPULAR SKIN DISEASE; PARESTHESIA; PHOTOSENSITIVITY; PRESCRIPTION; PROSTATE DISEASE; PRURITUS; PSORIASIS; PSYCHOSIS; RASH; RAYNAUD PHENOMENON; RECURRENT INFECTION; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; SKIN ALLERGY; SKIN DISEASE; SOMNOLENCE; SYNCOPE; TACHYCARDIA; THYMUS DISEASE; TOPICAL TREATMENT; TREMOR; URINE RETENTION; URTICARIA; VERTIGO; VOMITING; XEROSTOMIA;

EID: 18444399271     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(05)83987-9     Document Type: Short Survey

References (62)

1. Markman HD, Rosenberg P, Dettbarn WD. Eye drops and diarrhea. Diarrhea as the first symptom of echothiophate iodide toxicity. N Engl J Med 1964; 271: 197-9.
2. Davidson SI. Systemic effects of eye drops. Trans Ophthalmol Soc 1974; 94: 487-95.
3. Le Jeunne C, Hugues FC, Munera Y, Haas C. Systemic effects of eyedrops. Ann Med Interne 1990; 141: 674-7.
4. Fraunfelder FT, Meyer SM. Systemic reactions to ophthalmic drug preparations. Med Toxicol Adverse Drug Exp 1987; 2: 287-93.
5. Doucet J, Chassagne P. Affections iatrogéniques. Impact Internat 1997; 19: 425-31.
6. Queneau P, Grandmottet P. Prévention de la iatrogénie évitable: le devoir de vigilance. Presse Med 1998; 27: 1280-2.
7. Lapalus P, Moulin G, Fredj D. Kinetics of drugs in ophthalmology. Bull Soc Ophtalmol Fr 1985; Spec No: 31-48.
8. Schoenwald RD. Ocular pharmacokinetics. In: Zimmerman TJ, Kooner KS, Sharir M, Fechtner RD. Textbook of ocular pharmacology Lippincott-Raven, Philadelphia, 1997; 9: 119-38.
9. Shell JW. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol 1982; 26: 207-18.
10. Ueno N, Refojo MF, Abelson MB. Pharmakokinetics. In: Albert DA, Jakobiec FA. Principles and practice of ophthalmology. Basic sciences WB Saunders Company, Philadelphia, 1994; 74: 916-29.
11. Dupin O, Trinquand C. Les voies de pénétration endoculaire. J Fr Ophtalmol 2000; 23: 501-4.
12. Frangie JP. Clinical pharmacokinetics of various topical ophthalmic delivery systems. Clin Pharmacokinet 1995; 29: 130-8.
13. Friedrich SW, Cheng YL, Saville BA. Theoretical corneal permeation model for ionizable drugs. J Ocul Pharmacol 1993; 9: 229-49.
14. Netter P, Sirbat D, Trechot P. Systemic effects of ophthalmic solutions. Bull Soc Ophtalmol Fr 1985; Spec No; 255-75.
15. Ahmed I, Patton TF. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest Ophthalmol Vis Sci 1985; 26: 584-7.
16. Sasaki H, Ichikawa M, Kawakami S, Yamamura K, Nishida K, Nakamura J. In situ ocular absorption of tilisolol through ocular membranes in albino rabbits. J Pharm Sci 1996; 85: 940-3.
17. Dickstein K, Aarsland T. Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men. Am J Ophthalmol 1996; 121: 367-71.
18. von der Ohe N, Stark M, Mayer H, Brewitt H. How can the bioavailability of timolol be enhanced? A pharmacokinetic pilot study of novel hydrogels. Graefes Arch Clin Exp Ophthalmol 1996; 234: 452-6.
19. Bar-Ilan A, Neumann R. Basic considerations of ocular drug-delivery systems. In: Zimmerman TJ, Kooner KS, Sharir M, Fechtner RD. Textbook of ocular pharamcology. Lipincott-Raven, Philadelphia 1997; 10: 139-50.
20. Wei CP, Anderson JA, Leopold I. Ocular absorption and metabolism of topically applied epinephrine and a dipivalyl ester of epinephrine. Invest Ophthalmol Vis Sci 1978; 17: 315-21.
21. Mandell AI, Stentz F, Kitabchi AE. Dipivalyl epinephrine: a new pro-drug in the treatment of glaucoma. Ophthalmology 1978; 85: 268-75.
22. Ramselaar JA, Boot JP, van Haeringen NJ, van Best JA, Oosterhuis JA. Corneal epithelial permeability after instillation of ophthalmic solutions containing local anaesthetics and preservatives. Curr Eye Res 1988; 7: 947-50.
23. Poirier RH, Kingham JD, deMiranda P, Annel M. Intraocular antiviral penetration. Arch Ophthalmol 1982; 100: 1964-7.
24. Yamada Y, Takayanagi R, Tsuchiya K, Ito K, Ohtani H, Sawada Y et al. Assessment of systemic adverse reactions induced by ophthalmic beta-adrenergic receptor antagonists. J Ocul Pharmacol Ther 2001; 17: 235-48.
25. Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol 1984; 102: 551-3.
26. Elibol O, Alcelik T, Yuksel N, Caglar Y. The influence of drop size of cyclopentolate, phenylephrine and tropicamide on pupil dilatation and systemic side effects in infants. Acta Ophthalmol Scand 1997; 75: 178-80.
27. Robin AL. The role of alpha-agonists in glaucoma therapy. Curr Opin Ophthalmol 1997;8:42-9.
28. Yuksel N, Guler C, Caglar Y, Elibol O. Apraclonidine and clonidine: a comparison of efficacy and side effects in normal and ocular hypertensive volunteers. Int Ophthalmol 1992; 16: 337-42.
29. Sirbat D, Marchal-Heussler L, Hoffman M, Maincent P. Moyens d'amélioration de la biodisponibilité pour la voie topique. J Fr Ophtalmol 2000; 23: 505-9.
30. Urtti A, Rouhiainen H, Kaila T, Saano V. Controlled ocular timolol delivery: systemic absorption and intraocular pressure effects in humans. Pharm Res 1994; 11: 1278-82.
31. Friedrich SW, Saville BA, Cheng YL, Rootman DS. Pharmacokinetic differences between ocular inserts and eyedrops. J Ocul Pharmacol Ther 1996; 12: 5-18.
32. Marchal-Heussler L, Sirbat D, Hoffman M, Maincent P. Nanocapsules of beta-blocking agents: a new drug carrier in ophthalmology. Application to medical treatment of glaucoma in rabbits. J Fr Ophtalmol 1991; 14: 371-5.
33. Behar-Cohen FF, El Aouni A, Gautier S, David G, Davis J, Chapon P et al. Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels. Exp Eye Res 2002; 74: 51-9.
34. Taniguchi T, Kitazawa Y. The potential systemic effect of topically applied beta-blockers in glaucoma therapy. Curr Opin Ophthalmol 1997; 8: 55-8.
35. Gerber SL, Cantor LB, Brater DCK. Systemic drug interactions with topical glaucoma medications. Surv Ophthalmol 1990; 35: 205-18.
36. Diamond JP. Systemic adverse effects of topical ophthalmic agents. Implications for older patients. Drugs Aging 1997; 11: 352-60.
37. Le Jeunne C, Munera Y, Hugues FC. Systemic effects of three beta-blocker eyedrops: comparison in healthy volunteers of beta 1- and beta 2-adrenoreceptor inhibition. Clin Pharmacol Ther 1990; 47: 578-83.
38. Hugues FC, Le Jeunne C, Munera Y, Dufier JL. Comparison of the effects of carteolol and metipranolol eyedrops on the ventilatory and cardiovascular functions in asthmatics. J Fr Ophthalmol 1987; 10: 485-90.
39. Hugues FC, Le Jeunne C, Munera Y, Dufier JL. Evaluation of the systemic effects of timolol maleate in eye drops. J Fr Ophtalmol 1985; 8: 389-94.
40. Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L. Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol. J Clin Pharmacol 1989; 29: 97-101.
41. Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kuritsky JN. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am J Ophthalmol 1986; 102: 606-11.
42. Resales T, Isenberg S, Leake R, Everett S. Systemic effects of mydriatics in low weight infants. J Pediatr Ophthalmol Strabismus 1981; 18: 42-4.
43. Merli GJ, Weitz H, Martin JH, McClay EF, Adler AG, Fellin FM et al. Cardiac dysrhythmias associated with ophthalmic atropine. Arch Intern Med 1986; 146: 45-7.
44. Barker DB, Solomon DA. The potential for mental status changes associated with systemic absorption of anticholinergic ophthalmic medications: concerns in the elderly. DICP 1990; 24: 847-50.
45. Tune LE, Bylsma FW, Hilt DC. Anticholinergic delirium caused by topical homatropine ophthalmologic solution: confirmation by anticholinergic radioreceptor assay in two cases. J Neuropsychiatry Clin Neurosci 1992; 4: 195-7.
46. Van Buskirk EM. Adverse reactions from timolol administration. Ophthalmology 1980; 87: 447-50.
47. Zimmerman TJ. Topical ophthalmic beta blockers: a comparative review. J Ocul Pharmacol 1993; 9: 373-84.
48. Detry-Morel M, Dutrieux C. Treatment of glaucoma with brimonidine (Alpha-gan 0.2%). J Fr Ophtalmol 2000; 23: 763-8.
49. Talluto DM, Wyse TB, Krupin T. Topical carbonic anhydrase inhibitors. Curr Opin Ophthalmol 1997; 8: 2-6.
50. Hejkal TW, Camras CB. Prostaglandin analogs in the treatment of glaucoma. Semin Ophthalmol 1999; 14: 114-23.
51. Roters S, Aspacher F, Diestelhorst M. The influence of dexamethasone 0.1% eye drops on plasma cortisol and ACTH concentrations after cataract surgery. Ophthalmological 1996;210:211-4.
52. Krupin T, Mandell AI, Podos SM, Becker B. Topical corticosteroid therapy and pituitary-adrenal function. Arch Ophthalmol 1976; 94: 919-20.
53. Burch PG, Migeon CJ. Systemic absorption of topical steroids. Arch Ophthalmol 1968; 79: 174-6.
54. Salminen L. Review: systemic absorption of topically applied ocular drugs in humans. J Ocul Pharmacol 1990; 6: 243-9.
55. Ozerdem U, Levi L, Cheng L, Song MK, Scher C, Freeman WR. Systemic toxicity of topical and periocular corticosteroid therapy in an 11-year-old male with posterior uveitis. Am J Ophthalmol 2000; 130: 240-1.
56. Steelman J, Kappy M. Adrenal suppression and growth retardation from ocular corticosteroids. J Pediatr Ophthalmol Strabismus 2001; 38: 177-8.
57. Weijtens O, Schoemaker RC, Cohen AF, Romijn FP, Lentjes EG, van Rooij J et al. Dexamethasone concentration in vitreous and serum after oral administration. Am J Ophthalmol 1998; 125: 673-9.
58. Sheehan GJ, Kutzner MR, Chin WD. Acute asthma attack due to ophthalmic indomethacin. Ann Intern Med 1989; 111: 337-8.
59. Sitenga GL, Ing EB, Van Dellen RG, Younge BR, Leavitt JA. Asthma caused by topical application of ketorolac. Ophthalmology 1996; 103: 890-2.
60. Robert PY, Adenis JP. Comparative review of topical ophthalmic antibacterial preparations. Drugs 2001; 61: 175-85.
61. Walker S, Diaper CJ, Bowman R, Sweeney G, Seal DV, Kirkness CM. Lack of evidence for systemic toxicity following topical chloramphenicol use. Eye 1998; 12: 875-9.
62. Fraunfelder FT, Meyer SM. Ocular toxicology update. Aust J Ophthalmol 1984; 12: 391-4.